Here's Why We're Watching Alector's (NASDAQ:ALEC) Cash Burn Situation
Barclays Sticks to Their Buy Rating for Alector (ALEC)
Alector Is Maintained at Buy by HC Wainwright & Co.
Alector Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Alector (ALEC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $41.00 to $35.00.
HC Wainwright & Co. : The Alector (ALEC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $41.00 to $35.00.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $35
HC Wainwright & Co. analyst Andrew Fein maintains Alector (NASDAQ:ALEC) with a Buy and lowers the price target from $41 to $35.
Cantor Fitzgerald: Reiterates Alector (ALEC.US) shareholding rating.
Cantor Fitzgerald: Reiterates Alector (ALEC.US) shareholding rating.
Cantor Fitzgerald Reiterates Overweight on Alector
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Alector with a Overweight.
Alector Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 — Cantor Fitzgerald Reiterates → Overweight 02/28/2024 686.03% HC Wainwright & Co. → $41 Reite
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
Alector Q1 EPS $(0.38) Beats $(0.51) Estimate, Sales $15.89M Beat $14.80M Estimate
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.51) by 25.49 percent. This is a 30.91 percent increase over losses of $(0.55) per
Alector | 10-Q: Quarterly report
Press Release: Alector Reports First Quarter 2024 Financial Results and Provides Business Update
Alector Reports First Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's diseas
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S.,
Insider Sellers Might Regret Selling Alector Shares at a Lower Price Than Current Market Value
Despite the fact that Alector, Inc.'s (NASDAQ:ALEC) value has dropped 12% in the last week insiders who sold US$709k worth of stock in the past 12 months have had less success.
The Past Five Years for Alector (NASDAQ:ALEC) Investors Has Not Been Profitable
Alector Inc Announces Board Retirement and New Members
Alector's Clinical Progress and Financial Health Anchor Buy Recommendation
Alector(ALEC.US) Officer Sells US$41,553.92 in Common Stocks
$Alector(ALEC.US)$ Officer Romano Gary sold 6,001 shares of Common Stocks on Mar 4, 2024 at an average price of $6.9245 for a total value of $41,553.92.Source: Announcement What is statement of change
Alector(ALEC.US) Officer Sells US$70,386.77 in Common Stocks
$Alector(ALEC.US)$ Officer Kenkare-Mitra Sara sold 10,169 shares of Common Stocks on Mar 4, 2024 at an average price of $6.9217 for a total value of $70,386.77.Source: Announcement What is statement o
Alector(ALEC.US) Officer Sells US$130.39K in Common Stocks
$Alector(ALEC.US)$ Officer Rosenthal Arnon sold 18,837 shares of Common Stocks on Mar 4, 2024 at an average price of $6.9218 for a total value of $130.39K.Source: Announcement What is statement of cha
No Data